ARIYA HAQ: Open Payments
NPI 1740967678 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,499 in 103 payments from 21 companies in 2025. Trend: 2023 $924 · 2024 $1,622 · 2025 $2,499
Food & beverage: $2,499
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 16 | $323 |
| Regeneron Healthcare Solutions, Inc. | 10 | $315 |
| Novartis Pharmaceuticals Corporation | 10 | $278 |
| GlaxoSmithKline, LLC. | 11 | $229 |
| Organon LLC | 8 | $181 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $157 |
| Genentech USA, Inc. | 5 | $142 |
| Grifols USA, LLC | 4 | $117 |
| BioCryst US Sales Co., LLC | 5 | $95 |
Products named: DUPIXENT, Xolair, TRELEGY ELLIPTA, NEFFY, FASENRA, VTAMA, Rhapsido, Gamunex-C.
Industry payments across TX — which companies pay providers there.
